pipette
ESEspañol

Immune Defense Protein IDP Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study

A. D. Grant, C. S. Prideaux, M. Rosales, L. Capano-Wehrle, J. Moos, N. Mkrtytchian, V. Luna, M. C. E. Krupa, N. Craft

PreprintReal-world use

In the authors' words

Background. Upper respiratory infections are common and carry a greater burden in older adults. IDP (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods. This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP /day, and advanced dose of 200mg IDP /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results. N=255 participants (n=88 Placebo, n=85 50 mg IDP , n=82 200 mg IDP ) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP and 200 mg IDP groups compared to Placebo (KW for Area Under the Curve p<0.05). ANCOVA of baseline to Week-16 change and MRMM of total WURSS-24 symptom frequency, severity and rescue medication use revealed no significant difference between arms (ANCOVA and MRMM p > 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions. Sixteen weeks of daily IDP supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP appears safe and tolerable.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, November 17. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.09.26367685